43. In an experimental study, researchers are testing a new flea preventive medication on dogs using a blind study. Dogs are treated with the new medication or with a placebo. Who should know which dogs are given the medication or the placebo for this blind study?
Answer: B
Only the researchers should know which dogs are given the medication or the placebo.
In a blind study, it is crucial that the researchers are aware of which dogs receive the medication and which receive the placebo to ensure proper administration and monitoring of the treatment effects. This knowledge helps maintain the integrity of the study while minimizing bias.
A) Neither the researchers nor the dog owners nor the response gatherers
This option is incorrect because if neither the researchers nor any involved parties know which dogs received the treatment or placebo, it would hinder the ability to accurately monitor and assess the effects of the medication. The researchers need this information for effective data collection and analysis.
B) Only the researchers
This option is correct as it aligns with the principles of a blind study. The researchers need to know which dogs receive the treatment to administer it properly and evaluate the outcomes without biasing the results through interactions with dog owners or response gatherers.
C) The researchers, the dog owners, and the response gatherers
This option is incorrect because if dog owners and response gatherers know which dogs are receiving the medication, it could introduce bias into their perceptions and behaviors, potentially affecting the study's outcomes. Keeping this information limited to researchers helps ensure unbiased data collection.
D) Only the dog owners
This option is incorrect as allowing only dog owners to know which dogs receive the medication would also introduce bias. Owners may unintentionally influence the dog's behavior or observations based on their knowledge of the treatment, compromising the study's integrity.
Conclusion
The correct answer is B because it preserves the integrity of the blind study by allowing only the researchers to know which dogs are treated with the new medication or placebo. This minimizes potential biases from dog owners and response gatherers, ensuring that the results reflect the true efficacy of the medication being tested. All other options fail to maintain the necessary objectivity required for reliable experimental outcomes.